NanoSyrinx
nanosyrinx.com
Actively hiring
Synthetic Biology
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
News
Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines 25+ years of biotherapeutics leadership, including serving as founding CEO of two NASDAQ-listed companies and securing over $5
Read more
Report
Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
NanoSyrinx, a synthetic biology company developing Nanosyringes as a novel platform for targeted intracellular delivery of biologic therapeutics, today announced the appointment of Thomas J. Farrell as Chief Executive Officer and Director. Tom succeeds co
Read more
Report
Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
Read more
Report
NanoSyrinx featured in Nature Biopharma Dealmakers
NanoSyrinx is delighted to have been featured in Nature's Biopharma Dealmakers in an in-depth article exploring how the company is engineering bacterial nanomachines into a new therapeutic modality for targeted intracellular protein delivery. The article
Read more
Report
NanoSyrinx strengthens senior R&D team
Appointments of Dr Valentina Galli as Associate Research Director, Translational Biology, and Steve Ruscoe as Principal Scientist, Process Development Drug delivery and process development expertise further expands the Company's R&D capabilities Coventry,
Read more
Report
Meet our science and scientists at SITC and EORTC
Members from the NanoSyrinx team will be on the road over the coming weeks presenting exciting data from our internal developments and recent collaborations. If you'd like to learn more about our science and meet some of the talented folks responsible for
Read more
Report
NanoSyrinx secures funds to develop biologic therapeutics
The company secured £10m in the funding round jointly-led by BGF, Octopus Ventures and M Ventures.
Read more
Report
NanoSyrinx closes £10 million GBP financing and appoints Dr. Edwin Moses as Chairman
Round co-led by BGF, Octopus Ventures and M Ventures, with support from new corporate investor, Eli Lilly and Company, and existing investors, IQ Capital and Meltwind Appointment of Edwin Moses as Chairman to support the leadership team in maximising the
Read more
Report
NanoSyrinx highlighted in Cell Trends
Our CEO Joe Healey was recently invited to write a piece for Cell Trends' "Industry Highlights", which is now available online here. These articles offer short reads about up and coming companies and technologies that are making waves in the industry. Nan
Read more
Report
NanoSyrinx CEO Joe Healey appointed to DSIT's Engineering Biology Steering Group
In 2023, the UK Government published the "National Vision for Engineering Biology". The report highlighted the ambitions of the UK to be a world leader in the Engineering Biology (a.k.a. Synthetic Biology) sector, and described how £2BN would be put to wo
Read more
Report
Show more news